Eledon Pharmaceuticals (ELDN) Preferred Stock Liabilities (2013 - 2026)

Eledon Pharmaceuticals has reported Preferred Stock Liabilities for 7 years, with the latest figure at $53.5 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $53.5 million; the trailing twelve-month figure through Mar 2026 stood at $53.5 million (changed 0.0% YoY), and the FY2025 full-year result was $53.5 million, up 2389.21% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $53.5 million, roughly flat from $53.5 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $53.5 million in Q1 2025, with the low at $2.2 million in Q4 2023.
• Historically, Preferred Stock Liabilities has averaged $20.9 million across 5 years, with a median of $2.2 million in 2023.
• Annual changes were most pronounced in 2023 — Preferred Stock Liabilities slipped 28.7% — and 2025, when it surged 2389.21%.
• Eledon Pharmaceuticals' Preferred Stock Liabilities stood at $3.0 million in 2022, then fell by 28.7% to $2.2 million in 2023, then changed by 0.0% to $2.2 million in 2024, then surged by 2389.21% to $53.5 million in 2025, then changed by 0.0% to $53.5 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $53.5 million (Q1 2026), $53.5 million (Q4 2025), and $53.5 million (Q3 2025), per Business Quant data.